摘要
目的:探讨腹腔内贝伐珠单抗联合热化疗治疗老年卵巢癌的效果及对患者血清转化生长因子-β1(TGF-β1)、巨噬细胞移动抑制因子(MIF)表达的影响。方法:选取2015年1月-2017年1月本院收治的63例老年卵巢癌患者为研究对象。按照随机数字表法将其分为对照组31例和观察组32例。对照组给予腹腔内热化疗治疗,观察组给予腹腔内贝伐珠单抗联合热化疗治疗。比较两组的临床疗效、血清TGF-β1、MIF水平,不良反应发生情况及生存率。结果:观察组治疗总有效率为78.13%,高于对照组的51.61%,差异有统计学意义(P<0.05)。治疗后,两组血清TGF-β1、MIF均下降。观察组血清TGF-β1、MIF均低于对照组,差异均有统计学意义(P<0.05)。两组化疗不良反应及贝伐珠单抗不良反应发生率比较,差异均无统计学意义(P>0.05)。观察组1、2年生存率均高于对照组,差异均有统计学意义(P<0.05)。结论:腹腔内贝伐珠单抗联合热化疗治疗老年卵巢癌能够提高肿瘤控制效果,降低血清TGF-β1、MIF水平,提高远期生存率,且不会明显增加不良反应。
Objective:To investigate the efficacy of intraperitoneal Bevacizumab combined with thermochemotherapy in the treatment of elderly ovarian cancer and its effect on the expression of transforming growth factor-β1(TGF-β1)and macrophage mobile inhibitory factor(MIF).Method:Sixty-three elderly patients with ovarian cancer admitted to our hospital from January 2015 to January 2017 were selected as research objects.According to the random number table method,they were divided into control group 31 cases and observation group 32 cases.The control group was treated with intraperitoneal thermochemotherapy,the observation group was treated with intraperitoneal Bevacizumab combined with thermochemotherapy.The clinical efficacy,serum TGF-β1,MIF levels,adverse reactions and survival rates of the two groups were compared.Result:The total effective rate was 78.13%in the observation group,it was higher than 51.61%in the control group,with statistically significant difference(P<0.05).After treatment,serum TGF-β1 and MIF decreased in both groups.The serum TGF-β1 and MIF in the observation group were all lower than those in the control group,the differences were statistically significant(P<0.05).Comparison of adverse reactions of chemotherapy and Bevacizumab between the two groups,the differences were not statistically significant(P>0.05).The 1-year and 2-year survival rates in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Intraperitoneal Bevacizumab combined with thermochemotherapy in the treatment of elderly ovarian cancer can improve the tumor control effect,reduce serum TGF-β1,MIF levels,improve long-term survival rate,without significantly increasing adverse reactions.
作者
陈晓明
郭莉媛
CHEN Xiaoming;GUO Liyuan(Jiamusi City Cancer and Tuberculosis Hospital,Jiamusi 154002,China;不详)
出处
《中国医学创新》
CAS
2020年第21期31-35,共5页
Medical Innovation of China
